Cosmetology & Trichology ஜர்னல்

Aims: To present follow-up data regarding previously published study on vacuum therapy alongside the use of cosmetic emulsions containing plant bioactive compounds used for treatment of androgenetic alopecia (AAG), female pattern hair loss (APF) and telogen effluvium (TE) and associated symptoms.

Methods: The 07 participants from the initial study (n=25) who suffered from more severe cases of hormonal androgenic/estrogenic alopecia accompanied or not by effluvia were selected by a multidisciplinary team for follow up. These participants were followed up for 10 months after the initial study had concluded (D=57 days) by means of clinical and dermatological evaluations utilizing a digital microscope USB 1600; questionnaires were also used to assess subjective perception of the participants. 07 participants from the initial study (n=25) who suffered from more severe cases of hormonal androgenic/estrogenic alopecia accompanied or not by effluvia were selected by a multidisciplinary team for follow up. These participants were followed up for 10 months after the initial study had concluded (D=57 days) by means of clinical and dermatological evaluations utilizing a digital microscope USB 1600; questionnaires were also used to assess subjective perception of the participants.

Results: The benefits of activating capillaries utilizing vasodilating negative pressure at short, medium and long term were evident, making it clear this technology has applications. In part I of the study the efficacy of vacuum therapy alongside other dermatological procedures was assessed by both a dermatologist and a trichologist at the start and at the end of the study after 57 days. In part II of the study, the same team of researchers observed that 29% of the participants showed intense hair growth (n=02), 42% showed moderate hair growth (n=03) and 29% showed light hair growth (n=03) after therapeutic interventions had concluded.

Conclusion: Participants demonstrated increased hair growth 10 months after therapeutic interventions had ceased, with no further need of any home care hair products. These results evidence the effectiveness of the therapies previously employed for treatment and symptom remission of AAG, AGA and TE.

Psoriasis is an autoimmune disease that affects nearly about 2%-3% of population across the globe. Role of biologics in moderate to severe psoriasis increased after observing efficacy of TNF-alpha antagonist such as etanercept, infliximab. The USFDA approved risankizumab in 2019 in the treatment of moderate to severe plaque psoriasis. This drug targets interleukin-23 (IL-23 by binding to its subcomponent, the protein p19. The results of landmark trials UltIMMa-1 and UltIMMa-2, IMMvent, IMMerge and IMMhance along with SustaIMM is a phase II/III trial shows that risankizumab effective at 150 mg every 12 weeks after initial two doses at week-0 and 4. Improvement of disease activity measured as PASI 90/ sPGA 0/1 or other outcomes favors risankizumab over placebo or adalimumab or ustekinumab at week 16 and 52. Long-term follow-up findings also consistent with its earlier outcomes. Risankizumab well tolerated and no major TRAEs observed in the short term, long term and during follow-up studies. Pharamacoeconomic analysis using ICER favors risankizumab due to its incremental gains due to improved quality of life and DALY. Risankizumab considered as enticing option for treating physician and patients incase patients with moderate to severe psoriasis.